SEC Form 4 · accession 0001209191-19-007761
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Altshuler
Officer — EVP, Global Research and CSO
Period of report
Feb 4, 2019
Accepted (ET)
Feb 6, 2019 · 4:46 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 4, 2019 | M | 1,796 | $91.05 | A | 40,909 | D | |
| Common Stock | Feb 4, 2019 | S | 1,796 | $189.19 | D | 39,113 | D | |
| Common Stock | Feb 4, 2019 | M | 2,330 | $86.52 | A | 41,443 | D | |
| Common Stock | Feb 4, 2019 | S | 2,330 | $189.19 | D | 39,113 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $91.05 | Feb 4, 2019 | M | 1,796 | D | — | Feb 1, 2026 | Common Stock | 1,796 | 7,184 | D |
| Stock Option (Right to Buy)F3 | $86.52 | Feb 4, 2019 | M | 2,330 | D | — | Feb 2, 2027 | Common Stock | 2,330 | 18,639 | D |
Explanation of responses
- F1Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1.
- F2The option vests in 16 quarterly installments from 02/02/2016.
- F3The option vests in 16 quarterly installments from 02/03/2017.